Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies

View/ Open
Author(s)
Shigdar, Sarah
Ward, Alister C
De, Abhijit
Yang, Chaoyong J
Wei, Mingqian
Duan, Wei
Griffith University Author(s)
Year published
2011
Metadata
Show full item recordAbstract
Haematological malignancies result from a heterogeneous mix of genetic mutations and chromosome aberrations and translocations. Targeted therapies, such as the anti-CD20 antibody rituximab, or the BCR-ABL inhibitor imatinib, have proven to be effective treatments in the management of some of these malignancies, though relapsing or refractory disease is still common. Nucleic acid-based therapies have also entered the clinical arena, providing an alternative, complementary approach. The forerunner of these therapies were the antisense oligonucleotides, but their scope has expanded to include siRNA, microRNA, decoy oligonucleotides ...
View more >Haematological malignancies result from a heterogeneous mix of genetic mutations and chromosome aberrations and translocations. Targeted therapies, such as the anti-CD20 antibody rituximab, or the BCR-ABL inhibitor imatinib, have proven to be effective treatments in the management of some of these malignancies, though relapsing or refractory disease is still common. Nucleic acid-based therapies have also entered the clinical arena, providing an alternative, complementary approach. The forerunner of these therapies were the antisense oligonucleotides, but their scope has expanded to include siRNA, microRNA, decoy oligonucleotides and aptamers. These can be used either as mono-therapeutics, in conjunction with current chemotherapy regimens, or in combination with each other to improve therapeutic efficacy. Not only can these nucleic acid-based therapies silence target genes, they also have the potential of restoring gene function. While challenges remain in delivering effective doses of nucleic acid in vivo, these are steadily being met, suggesting an optimistic future in the treatment of haematological malignancies. This review summarises the application of nucleic acid-based therapeutics, particularly aptamers, in the diagnosis and treatment of haematological malignancies.
View less >
View more >Haematological malignancies result from a heterogeneous mix of genetic mutations and chromosome aberrations and translocations. Targeted therapies, such as the anti-CD20 antibody rituximab, or the BCR-ABL inhibitor imatinib, have proven to be effective treatments in the management of some of these malignancies, though relapsing or refractory disease is still common. Nucleic acid-based therapies have also entered the clinical arena, providing an alternative, complementary approach. The forerunner of these therapies were the antisense oligonucleotides, but their scope has expanded to include siRNA, microRNA, decoy oligonucleotides and aptamers. These can be used either as mono-therapeutics, in conjunction with current chemotherapy regimens, or in combination with each other to improve therapeutic efficacy. Not only can these nucleic acid-based therapies silence target genes, they also have the potential of restoring gene function. While challenges remain in delivering effective doses of nucleic acid in vivo, these are steadily being met, suggesting an optimistic future in the treatment of haematological malignancies. This review summarises the application of nucleic acid-based therapeutics, particularly aptamers, in the diagnosis and treatment of haematological malignancies.
View less >
Journal Title
British Journal of Haematology
Volume
155
Issue
1
Copyright Statement
© 2011 British Journal of Haematology. Published by Blackwell Publishing Ltd.. This is the pre-peer reviewed version of the following article: [Article Title], British J Haematology, 155(1), 2011, 3-13, which has been published in final form at http://dx.doi.org/10.1111/j.1365-2141.2011.08807.x.
Subject
Molecular medicine
Cardiovascular medicine and haematology
Cancer therapy (excl. chemotherapy and radiation therapy)